Refractory neurogenic detrusor overactivity

Cruz, Francisco; Martins-Silva, Carlos

doi:10.1111/j.1742-1241.2006.01182.x

Cited by 6 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BoNT/A is being used in an ever-increasing number of NDO patients and has become the first treatment option for refractory NDO in many centres [6]. Several reasons might explain the rapid widespread use of this treatment.…”

Section: Botulinum Toxin Type a Injections For Refractory Neurogenic mentioning

confidence: 99%

Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?

Martins-Silva

Cruz

2009

Current Opinion in Urology

View full text Add to dashboard Cite

Although still waiting for approval, BoNT/A detrusor injections can be safely offered to well informed patients with refractory neurogenic detrusor overactivity, as an alternative to more invasive therapies, such as bladder augmentation. Ongoing studies are expected to come up with the necessary information for definitive approval of BoNT/A in neurogenic detrusor overactivity patients. Regarding other possible applications such as idiopathic detrusor overactivity, benign prostatic enlargement and bladder pain syndrome/interstitial cystitis, its use should still be restricted to research centres in well designed clinical trials.

show abstract

Section: Botulinum Toxin Type a Injections For Refractory Neurogenic mentioning

confidence: 99%

Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?

Martins-Silva

Cruz

2009

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

“…Desensitization to RTX is by definition reversible [69]. Intravesical RTX was shown to restore continence in a subset of patients with idiopathic and neurogenic detrusor overactivity [203][204][205]. Although case reports indicated a therapeutic value for intravesical RTX in intersitital cystitis patients [138][139][140], larger controlled clinical studies failed to support these reports [141].…”

Section: Conclusion and Future Research Directionsmentioning

confidence: 99%

Resiniferatoxin: Nature’s Precision Medicine to Silence TRPV1-Positive Afferents

Szallasi

2023

IJMS

View full text Add to dashboard Cite

Resiniferatoxin (RTX) is an ultrapotent capsaicin analog with a unique spectrum of pharmacological actions. The therapeutic window of RTX is broad, allowing for the full desensitization of pain perception and neurogenic inflammation without causing unacceptable side effects. Intravesical RTX was shown to restore continence in a subset of patients with idiopathic and neurogenic detrusor overactivity. RTX can also ablate sensory neurons as a “molecular scalpel” to achieve permanent analgesia. This targeted (intrathecal or epidural) RTX therapy holds great promise in cancer pain management. Intra-articular RTX is undergoing clinical trials to treat moderate-to-severe knee pain in patients with osteoarthritis. Similar targeted approaches may be useful in the management of post-operative pain or pain associated with severe burn injuries. The current state of this field is reviewed, from preclinical studies through veterinary medicine to clinical trials.

show abstract

“…Furthermore, 30–40% of children suffering from OAB does not respond to anti-muscarinic treatment. In some neurogenic OAB cases, these drugs even fail to relieve the symptoms and lead to refractory neurogenic detrusor overactivity [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB)

et al. 2023

View full text Add to dashboard Cite

Overactive bladder (OAB) is a symptomatic complex condition characterised by frequent urinary urgency, nocturia, and urinary incontinence with or without urgency. Gabapentin is an effective treatment for OAB, but its narrow absorption window is a concern, as it is preferentially absorbed from the upper small intestine, resulting in poor bioavailability. We aimed to develop an extended release, intragastric floating system to overcome this drawback. For this purpose, plasticiser-free filaments of PEO (polyethylene oxide) and the drug (gabapentin) were developed using hot melt extrusion. The filaments were extruded successfully with 98% drug loading, possessed good mechanical properties, and successfully produced printed tablets using fused deposition modelling (FDM). Tablets were printed with varying shell numbers and infill density to investigate their floating capacity. Among the seven matrix tablet formulations, F2 (2 shells, 0% infill) showed the highest floating time, i.e., more than 10 h. The drug release rates fell as the infill density and shell number increased. However, F2 was the best performing formulation in terms of floating and release and was chosen for in vivo (pharmacokinetic) studies. The pharmacokinetic findings exhibit improved gabapentin absorption compared to the control (oral solution). Overall, it can be concluded that 3D printing technology is an easy-to-use approach which demonstrated its benefits in developing medicines based on a mucoadhesive gastroretentive strategy, improving the absorption of gabapentin with potential for the improved management of OAB.

show abstract

Refractory neurogenic detrusor overactivity

Cited by 6 publications

References 57 publications

Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?

Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?

Resiniferatoxin: Nature’s Precision Medicine to Silence TRPV1-Positive Afferents

Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB)

Contact Info

Product

Resources

About